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Interleukin-12: A master regulator
Early resistance to pathogens requires a swift response from NK cells. In 
1989, Giorgio Trinchieri identified an NK growth factor and activator, later 
called interleukin-12 (IL-12). This discovery helped reveal the regulatory link 
between innate and adaptive immunity.
NK cells were discovered in the early 
1970s and were immediately embraced 
by cancer researchers for their ability to 
spontaneously attack and lyse tumor cells 
(1). Over the next 10 years, the basic biol-
ogy of these cells was worked out: where 
they lurked, how they recognized their 
targets, and how they killed. Despite this 
trove of information, how the cells grew 
in vitro and what signals activated them 
in vivo remained unknown.
Growing killer cells
In the mid-1980s, researchers figured out 
how to isolate NK cells from peripheral 
blood mononuclear cells and maintain 
them in cultures containing the T cell-
specific growth factor IL-2 (2). But these 
methods produced low numbers of NK 
cells and supported only short-term 
growth of NK cell clones.
Trinchieri and his team at the Wistar 
Institute in Philadelphia had found that a 
relatively large and pure population of 
NK cells could be generated by culturing 
mononuclear cells with irradiated B cell 
lines that had been immortalized by the 
Epstein-Barr Virus (3). They assumed 
that the dying B cells were secreting 
growth factors that favored NK cell 
proliferation. Cytokines such as IL-2, 
IL-1, IFNα/β/γ, and IL-6 were present 
in the cultures but could not support 
NK cell growth without B cells, sug-
gesting that a direct cell–cell signal or an 
unknown growth factor was at work.
A novel cytokine
Although Trinchieri was intrigued by the 
identity of this potential growth factor, 
the primary interest of his team at that 
time was the ability of NK cells to regulate 
the differentiation of bone marrow stem 
cells. Trinchieri’s team had discovered 
that NK cells inhibited the colony-
forming ability of hematopoietic progeni-
tor cells and induced their differentiation 
by secreting so-called “cytotoxic factors” 
and “colony-inhibiting factors” (4). The 
identification of TNF as the cytotoxic 
factor was easy since recombinant TNF 
protein was readily available. The team 
took longer, however, to purify lympho-
toxin (LT), the putative source of the 
colony-inhibiting activity (5).
Michiko Kobayashi, a biochemist and 
purification expert on temporary loan 
from the Genetics Institute (Cambridge, 
MA), discovered IL-12 during her efforts 
to purify LT. She had generated massive 
quantities of supernatents from B cell 
cultures for this project. She and 
Trinchieri reasoned that this soup might 
also contain NK cell growth factors. 
Using standard chromatography based 
separation techniques, she fractionated 
the cell-free supernatents and tested each 
eluted fraction for its ability to induce the 
three known functions of NK cells: IFNγ 
production, cytotoxic activity against 
tumor cell lines, and enhanced prolifer-
ation in response to mitogens.
The sole fraction that tested positive 
for all three functions was purified and 
proven to be a potent NK cell stimulator. 
The NK-stimulating factor, as the mys-
tery protein was called before it was re-
named IL-12, was composed of 30- and 
40-kD covalently bound subunits, and 
was the first heterodimeric cytokine to be 
described. The team published their 
discovery in The Journal of Experimental 
Medicine in 1989 (6). “We would have 
never found IL-12 if it hadn’t been for 
our efforts to purify LT or for Michiko’s 
refusal to waste that supernatant,” says 
Trinchieri. “It was our bonus result.”
A regulatory bridge
IL-12 has since gained fame as some-
thing of an immunological busybody. In 
collaboration with researchers at the 
DNAX Research Institute (Palo Alto, 
CA), Trinchieri later showed that the IL-
12 produced by dendritic cells induced 
naive CD4+ T cells to differentiate into T 
helper (Th)-1 cells (7), adaptive immune 
cells that respond to infectious agents 
and cancer antigens. The ability of IL-12 
to promote an early nonspecific response 
via NK activation and IFNγ production 
and a late specific response via Th1 
differentiation allows it to link innate 
and adaptive immune mechanisms. 
Treatment with IL-12 abolishes mouse 
tumors and prevents tumor establish-
ment. This success has generated much 
interest in using IL-12 in human anti-
tumor therapies. But IL-12-induced 
Th1  cells have a dangerous flip-side: 
they drive the pathogenesis of many 
autoimmune disorders. IL-12 is currently 
under investigation as a therapeutic target 
for these diseases (8).
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